ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q46112511

about

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Stem cell transplantation in chronic lymphocytic leukemia Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia ZAP-70 in B cell malignancies Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia CD23/FcεRII: molecular multi-tasking Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL c MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL.Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience.Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

P2860

Q24315721-D124EC39-6652-4B6F-A034-4B13D2B50CC1 Q24616084-1149FDC4-D5DA-4556-A745-3DE21C59CF33 Q24642921-0CF08460-5931-4CBA-833C-FB2BB478E43C Q24657747-74937EF8-91B3-415E-BCD3-6A177815710B Q24681296-0E140EF0-9EEA-4F9F-8269-CD5A2ED92C27 Q26775986-5444790E-2A5F-4661-9D0E-C067E8AA812D Q26830323-BD4C5FFC-A8A7-4842-8A13-2043CEBB3C60 Q28082120-2B03E75A-5A2D-4F5D-823E-ED805C51813B Q28239225-36567BE5-5AD8-431B-B8E1-8A74B189DC2C Q28241703-D5D098E0-ACCD-4BAC-A0B4-D6383C10576D Q28245018-E17640C8-CBF3-4212-8D1E-F1A3D5465582 Q28261949-38FC93DF-39A7-46C7-8CBA-B4F59B11607A Q28262745-18BF2196-64FF-4923-B971-C8D1D55E15F3 Q28279902-E2EBB325-7867-489B-9FEB-FD21D8AA5AA8 Q28282822-4F565B2F-AA31-4438-8485-A190597C096E Q28315285-86659E6B-1F9F-46F8-9809-86F89B91DA5F Q28744086-AAE318C3-7C76-48C2-9F8D-091F10F0071D Q30356145-795234F6-7250-4394-B90B-756116A3ECD5 Q30405847-DD9FC278-482C-46B0-B2D0-1E81BFA45A92 Q30408922-70A2EEC1-869F-47D2-951E-15476A06500B Q30886103-BB3FDCBF-F55D-4221-8301-E283233C155F Q33330596-49534DFF-547D-472F-ACD1-52467EA460A0 Q33364071-5942E424-8B9E-4260-A0CE-62ECCE07E000 Q33409459-9E48B40E-413B-4F45-893B-FE176E5522A3 Q33421376-A4C4B74B-089B-46C7-A64F-47D8E356D359 Q33587644-1192094E-50CB-4B55-BEB5-2AD2DBCE9B83 Q33621881-1836DB1A-2E85-4FDB-A9A8-847AB1733A47 Q33634389-76D75CC4-D840-4987-AB7A-15CD4D804AF2 Q33638819-CBBE2389-F1BA-41AD-9E71-C89D5F1B54A1 Q33707448-50C53EC3-BF7A-41CE-AD4C-FEE56002FEF9 Q33708995-0A877360-E600-48AA-A900-5822C3E2D3B2 Q33758834-DBBF71B1-2BEC-4A49-A2DD-75712A458942 Q33770207-92E067F8-7D67-4BCA-91FD-B21E74936F93 Q33774513-EE4034C5-AD2C-46DD-8210-9DEA9074AACB Q33796183-21E84AE9-4C09-4015-80D8-F286DBAA11BD Q33814458-272BD636-41D2-4653-987C-887739EA1242 Q33822016-AB160EFA-C8D9-40FA-A39C-ABCB2660A19C Q33831931-521A50CA-F135-47F5-8027-9C71FE2C8A55 Q33886052-1FA02470-6F8D-49D0-8D67-5A84605F7AB8 Q33931707-4B372F31-8DBA-4D09-B3D2-7E2D1F194CFB

P2860

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q46112511

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

ZAP-70 compared with immunoglo ...... chronic lymphocytic leukemia.

@en

ZAP-70 compared with immunoglo ...... chronic lymphocytic leukemia.

@nl

type

label

ZAP-70 compared with immunoglo ...... chronic lymphocytic leukemia.

@en

ZAP-70 compared with immunoglo ...... chronic lymphocytic leukemia.

@nl

prefLabel

ZAP-70 compared with immunoglo ...... chronic lymphocytic leukemia.

@en

ZAP-70 compared with immunoglo ...... chronic lymphocytic leukemia.

@nl

P1433

Q46112511-C7F5C962-0425-42F5-A14A-C01D28589729

P1476

Q46112511-1B0BFD23-9AB8-4E6B-823D-36306785207D

P2093

Q46112511-02BE9B95-8C38-465E-9C48-D7171DDDA86D

Q46112511-49DD3CA3-28D1-4E14-8A3F-A14762A1E54E

Q46112511-7E126747-C254-4573-8EBC-F020CE9D02C0

Q46112511-8A4C2B39-221F-4DF0-BC76-E157D33A88CC

Q46112511-A88A9211-09D4-40A4-99AF-1FB4EBC897FD

Q46112511-ACA274DB-07D4-47E7-9C66-8969227CF2CF

Q46112511-B88A24D4-DE5C-4113-9C35-D9BEAACC416F

Q46112511-D6009E6D-CA48-48BD-A5B2-AC2B7DE1A8F5

Q46112511-D86F1D70-8E85-4BDD-94C0-42FDF32B5656

Q46112511-D8DC5371-6BCE-453D-91F5-13444338BA8C

P304

Q46112511-D531DC77-312F-48CE-8385-3584E07805F4

P31

Q46112511-BA521A26-044D-44B0-A908-B335D331A28C

P356

Q46112511-A677F978-B066-4568-8E70-D22F84A92B80

P407

Q46112511-37E7A933-099E-4962-B708-752537F49A93

P433

Q46112511-231F91BF-FDC8-4210-BB29-EDC4D83DFD7A

P478

Q46112511-6303B89F-026A-4EA3-99ED-968AD62B45BE

P50

Q46112511-32F6C82A-B0C5-41E1-897F-42F558DD8299

Q46112511-8DF9EEC3-9A1C-4E59-BCDB-F5227CA2C75B

Q46112511-920A63FE-497E-48FD-804C-1AFF4356A19E

P577

Q46112511-15F5DC33-27B2-41F4-8B4F-FE01648007A2

P698

Q46112511-0FC80833-C4BA-48A3-98A1-FEA77F6EC4A3

P921

Q46112511-88DE3293-F038-49F1-AA79-A33CB7855964

Q46112511-92D2C4FC-CD35-4805-872B-FEE1121B4085

P356

P1433

The New England Journal of Medicine

P1476

ZAP-70 compared with immunoglo ...... chronic lymphocytic leukemia.

@en

P2093

Andrew Greaves

http://www.w3.org/2001/XMLSchema#string

Donna S Neuberg

http://www.w3.org/2001/XMLSchema#string

Ian W Flinn

http://www.w3.org/2001/XMLSchema#string

John G Gribben

http://www.w3.org/2001/XMLSchema#string

Kanti R Rai

http://www.w3.org/2001/XMLSchema#string

Lang Huynh

http://www.w3.org/2001/XMLSchema#string

Laura Z Rassenti

http://www.w3.org/2001/XMLSchema#string

Liguang Chen

http://www.w3.org/2001/XMLSchema#string

Neil E Kay

http://www.w3.org/2001/XMLSchema#string

Thomas J Kipps

http://www.w3.org/2001/XMLSchema#string

P304

893-901

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA040857

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

351

http://www.w3.org/2001/XMLSchema#string

P50

Michael J. Keating

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15329427

http://www.w3.org/2001/XMLSchema#string

P921